ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Considering starting TRT although levels are not "clinically low" Feedback would be appreciated
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 201062" data-attributes="member: 13851"><p>Injectable T has been shown to have a greater impact on increasing HCT compared to transdermal T.</p><p></p><p>3–18% with transdermal administration and up to 44% with injection.</p><p></p><p>In most cases when using injectable T high supra-physiological peaks post-injection and <strong><em><u>overall T levels</u> (<u>running too high TT/FT level</u>)</em></strong> will have a big impact on increasing HCT.</p><p></p><p>Manipulating injection frequency by injecting more frequently using lower doses of T resulting in minimizing the peak--->trough and maintaining more stable levels may lessen the impact on HCT but it is not a given.</p><p></p><p><strong><em><u>As again running very high TT/FT levels will have a stronger impact on driving up HCT</u>.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>T formulation, the dose of T, genetics (polymorphism of the AR), age all play a role in the impact a trt protocol will have on blood markers (RBCs/hemoglobin/hematocrit).</em></strong></p><p></p><p></p><p>[URL unfurl="true"]https://www.excelmale.com/forum/threads/does-hematocrit-keep-increasing-after-testosterone-steady-state-how-often-to-check.13856/[/URL]</p><p></p><p>-------------------------------------------------------------------------------------------------</p><p></p><p></p><p><strong>Erythrocytosis Following Testosterone Therapy</strong></p><p>[ATTACH=full]14166[/ATTACH]</p><p></p><p></p><p><strong>Effects of T formulation</strong></p><p></p><p><u>Of the available T formulations, short-acting IM injections (TC and TE) have the highest incidence of erythrocytosis (approaching 40%).14 Recent studies support a unified hypothesis in which <em><strong>T formulation, dose, and pharmacokinetics collectively determine the risk of erythrocytosis by establishing the DURATION OF SUPRAPHYSIOLOGIC T LEVELS</strong></em></u><strong><em>.</em></strong>52 <u>T formulations that result in stable serum concentrations (pellets, transdermal gels and patches, and extended-release IM TU) result in a low incidence of erythrocytosis that is <strong><em>dependent on dose and serum level</em></strong> and independent of the duration of therapy</u>.11, 52, 67 The relation of individual T formulations and associated effects on average T levels and incidence of erythrocytosis are presented in Table 1.</p><p></p><p></p><p><strong>Conclusions</strong></p><p></p><p>Erythrocytosis is often a limiting variable in patients on TTh. <em><strong>Direct and indirect effects related to supraphysiologic T levels are believed to mediate the effects on erythrocytosis. The true mechanism of erythrocytosis and its role in thromboembolic events remains unclear, although some data support an increased risk of CV events resulting from T-induced erythrocytosis.</strong></em> Large multicenter randomized controlled trials are required to study TTh, its effects on Hb and Hct, and the clinical significance of treatment-induced increases in red blood cell mass.</p><p></p><p>-------------------------------------------------------------------------------------------------</p><p></p><p></p><p></p><p></p><p>Although injectables have been shown to have a greater impact on HCT.</p><p></p><p><strong><em>You can see even when using a transdermal formulation that maintains stable serum concentrations that the impact it has on HCT is <u>DEPENDANT ON THE DOSE AND SERUM LEVEL OF T</u>.</em></strong></p><p></p><p>Using higher doses of transdermal T and achieving higher TT/FT levels will have a great impact on HCT levels.</p></blockquote><p></p>
[QUOTE="madman, post: 201062, member: 13851"] Injectable T has been shown to have a greater impact on increasing HCT compared to transdermal T. 3–18% with transdermal administration and up to 44% with injection. In most cases when using injectable T high supra-physiological peaks post-injection and [B][I][U]overall T levels[/U] ([U]running too high TT/FT level[/U])[/I][/B] will have a big impact on increasing HCT. Manipulating injection frequency by injecting more frequently using lower doses of T resulting in minimizing the peak--->trough and maintaining more stable levels may lessen the impact on HCT but it is not a given. [B][I][U]As again running very high TT/FT levels will have a stronger impact on driving up HCT[/U]. T formulation, the dose of T, genetics (polymorphism of the AR), age all play a role in the impact a trt protocol will have on blood markers (RBCs/hemoglobin/hematocrit).[/I][/B] [URL unfurl="true"]https://www.excelmale.com/forum/threads/does-hematocrit-keep-increasing-after-testosterone-steady-state-how-often-to-check.13856/[/URL] ------------------------------------------------------------------------------------------------- [B]Erythrocytosis Following Testosterone Therapy[/B] [ATTACH type="full" alt="1621093517950.png"]14166[/ATTACH] [B]Effects of T formulation[/B] [U]Of the available T formulations, short-acting IM injections (TC and TE) have the highest incidence of erythrocytosis (approaching 40%).14 Recent studies support a unified hypothesis in which [I][B]T formulation, dose, and pharmacokinetics collectively determine the risk of erythrocytosis by establishing the DURATION OF SUPRAPHYSIOLOGIC T LEVELS[/B][/I][/U][B][I].[/I][/B]52 [U]T formulations that result in stable serum concentrations (pellets, transdermal gels and patches, and extended-release IM TU) result in a low incidence of erythrocytosis that is [B][I]dependent on dose and serum level[/I][/B] and independent of the duration of therapy[/U].11, 52, 67 The relation of individual T formulations and associated effects on average T levels and incidence of erythrocytosis are presented in Table 1. [B]Conclusions[/B] Erythrocytosis is often a limiting variable in patients on TTh. [I][B]Direct and indirect effects related to supraphysiologic T levels are believed to mediate the effects on erythrocytosis. The true mechanism of erythrocytosis and its role in thromboembolic events remains unclear, although some data support an increased risk of CV events resulting from T-induced erythrocytosis.[/B][/I] Large multicenter randomized controlled trials are required to study TTh, its effects on Hb and Hct, and the clinical significance of treatment-induced increases in red blood cell mass. ------------------------------------------------------------------------------------------------- Although injectables have been shown to have a greater impact on HCT. [B][I]You can see even when using a transdermal formulation that maintains stable serum concentrations that the impact it has on HCT is [U]DEPENDANT ON THE DOSE AND SERUM LEVEL OF T[/U].[/I][/B] Using higher doses of transdermal T and achieving higher TT/FT levels will have a great impact on HCT levels. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Considering starting TRT although levels are not "clinically low" Feedback would be appreciated
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top